Journal of Neuro-Oncology

, Volume 95, Issue 1, pp 135–139 | Cite as

CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission

  • Vittorio Stefoni
  • Alessandro Broccoli
  • Cinzia Pellegrini
  • Enrico Derenzini
  • Mariapaola Fina
  • Pier Luigi Zinzani
Case Report


Primary mediastinal large B-cell lymphoma (PMBCL) has been firstly described by Levitt et al. in 1982 and, by definition, it consists of an intrathoracic lymphoma without demonstrable evidence of extrathoracic disease, after careful clinical staging [1]. It is a distinct clinical and pathological entity, and it is thought to arise from thymic medullary B cells. It typically affects young women, during their third or fourth decade of life, and it presents with rather homogeneous clinical aspects related to rapidly growing mediastinal masses, such as cough, dyspnoea, chest pain; in a minority of cases, superior vena cava syndrome, jugular vein distension and mantle oedema may also be reported [1, 2]. Although it is a local invasive neoplasm, extranodal and distant dissemination, as well as marrow infiltration, tend to be quite rare at presentation [3].

Central nervous system (CNS) relapse of PMBCL is a rather infrequent complication, consisting of a difficult therapeutic...


Central Nervous System Involvement Aggressive Lymphoma Central Nervous System Relapse Central Nervous System Prophylaxis Secondary Central Nervous System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Levitt LJ, Aisenberg AC, Harris NL et al (1982) Primary non-Hodgkin’s lymphoma of the mediastinum. Cancer 50:2486–2492. doi: 10.1002/1097-0142(19821201)50:11<2486::AID-CNCR2820501138>3.0.CO;2-G CrossRefPubMedGoogle Scholar
  2. 2.
    Lazzarino M, Orlandi E, Paulli M et al (1993) Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distintive clinical and pathologic features. J Clin Oncol 11(12):2306–2313CrossRefPubMedGoogle Scholar
  3. 3.
    Savage KJ (2006) Primary mediastinal large B-cell lymphoma. Oncologist 11:488–495. doi: 10.1634/theoncologist.11-5-488 CrossRefPubMedGoogle Scholar
  4. 4.
    Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596–602CrossRefPubMedGoogle Scholar
  5. 5.
    Hill QA, Owen RG (2006) CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 20:319–332. doi: 10.1016/j.blre.2006.02.001 CrossRefPubMedGoogle Scholar
  6. 6.
    Van Besien K, Ha CS, Murphy S et al (1998) Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178–1184PubMedGoogle Scholar
  7. 7.
    Zinzani PL, Magagnoli M, Frezza G et al (1999) Isolated central nervous system relapse in aggressive non-Hodgkin’s lymphoma: the Bologna experience. Leuk Lymphoma 32:571–576CrossRefPubMedGoogle Scholar
  8. 8.
    Haioun C, Besson C, Lepage E et al (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 11:685–690. doi: 10.1023/A:1008394827806 CrossRefPubMedGoogle Scholar
  9. 9.
    Hollender A, Kvaloy S, Nome O et al (2002) Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol 13:1099–1107. doi: 10.1093/annonc/mdf175 CrossRefPubMedGoogle Scholar
  10. 10.
    Boehme V, Zeynalova S, Kloess M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma––a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 18:149–157. doi: 10.1093/annonc/mdl327 CrossRefPubMedGoogle Scholar
  11. 11.
    Lister A, Abrey LE, Sandlund JT (2002) Central nervous system lymphoma. Hematology (Am Soc Hematol Educ Program):283–296. doi: 10.1182/asheducation-2002.1.283
  12. 12.
    Van Besien K, Gisselbrecht C, Pfreundschuh M et al (2008) Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma 49:52–58. doi: 10.1080/10428190802311458 CrossRefPubMedGoogle Scholar
  13. 13.
    Bishop PC, Wilson WH, Pearson D et al (1999) CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 17:2479–2485CrossRefPubMedGoogle Scholar
  14. 14.
    Martelli MP, Martelli M, Pescarmona E et al (1998) MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. Ann Oncol 9:1027–1029. doi: 10.1023/A:1008412009667 CrossRefPubMedGoogle Scholar
  15. 15.
    Zinzani PL, Martelli M, De Renzo A et al (2001) Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 86:187–191PubMedGoogle Scholar
  16. 16.
    Zinzani PL, Martelli M, Poletti V et al (2008) Practice guidelines for the management of extranodal non-Hodgkin’s lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 93:1364–1371. doi: 10.3324/haematol.12742 CrossRefPubMedGoogle Scholar
  17. 17.
    Chua SL, Seymour JF, Streater J et al (2002) Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin’s lymphoma. Leuk Lymphoma 43:1783. doi: 10.1080/1042819021000006475 CrossRefPubMedGoogle Scholar
  18. 18.
    Tomita N, Kodama F, Kanamori H et al (2002) Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 95:576–580. doi: 10.1002/cncr.10699 CrossRefPubMedGoogle Scholar
  19. 19.
    Barosi G, Carella A, Lazzarino M et al (2006) Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 91:96–103PubMedGoogle Scholar
  20. 20.
    Franklin JL, Finlay J (2006) Leukemias and lymphomas: treatment and prophylaxis of the central nervous system. Curr Treat Options Neurol 8:335–345. doi: 10.1007/s11940-006-0023-9 CrossRefPubMedGoogle Scholar
  21. 21.
    Massenkeil G, Späth-Schwalbe E, Flath B et al (1998) Transient tetraparesis after intrathecal and high-dose systemic methotrexate. Ann Hematol 77:239–242. doi: 10.1007/s002770050450 CrossRefPubMedGoogle Scholar
  22. 22.
    Ferhanoglu B, Ongören S, Ar CM et al (2003) Intrathecal methotrexate-induced acute cerebellar syndrome. Ann Hematol 82:241–243PubMedGoogle Scholar
  23. 23.
    Dai MS, Ho CL, Chen YC et al (2000) Acute respiratory distress syndrome following intrathecal methotrexate administration: a case report and review of literature. Ann Hematol 79:696–699. doi: 10.1007/s002770000217 CrossRefPubMedGoogle Scholar
  24. 24.
    Benekli M, Güllü IH, Savaş MC et al (1996) Acute tumor lysis syndrome following intrathecal methotrexate. Leuk Lymphoma 22:361–363. doi: 10.3109/10428199609051770 CrossRefPubMedGoogle Scholar
  25. 25.
    Watterson J, Toogood I, Nieder M et al (1994) Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 74:3034–3041. doi: 10.1002/1097-0142(19941201)74:11<3034::AID-CNCR2820741122>3.0.CO;2-O CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Vittorio Stefoni
    • 1
  • Alessandro Broccoli
    • 1
  • Cinzia Pellegrini
    • 1
  • Enrico Derenzini
    • 1
  • Mariapaola Fina
    • 1
  • Pier Luigi Zinzani
    • 1
  1. 1.Institute of Hematology “L e A Seràgnoli”University of BolognaBolognaItaly

Personalised recommendations